BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32512818)

  • 21. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
    Nouri M; Caradec J; Lubik AA; Li N; Hollier BG; Takhar M; Altimirano-Dimas M; Chen M; Roshan-Moniri M; Butler M; Lehman M; Bishop J; Truong S; Huang SC; Cochrane D; Cox M; Collins C; Gleave M; Erho N; Alshalafa M; Davicioni E; Nelson C; Gregory-Evans S; Karnes RJ; Jenkins RB; Klein EA; Buttyan R
    Oncotarget; 2017 Mar; 8(12):18949-18967. PubMed ID: 28145883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC.
    Lee CF; Chen YA; Hernandez E; Pong RC; Ma S; Hofstad M; Kapur P; Zhau H; Chung LW; Lai CH; Lin H; Lee MS; Raj GV; Hsieh JT
    Clin Transl Med; 2022 Feb; 12(2):e695. PubMed ID: 35184376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X
    Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
    Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early human prostate adenocarcinomas harbor androgen-independent cancer cells.
    FiƱones RR; Yeargin J; Lee M; Kaur AP; Cheng C; Sun P; Wu C; Nguyen C; Wang-Rodriguez J; Meyer AN; Baird SM; Donoghue DJ; Haas M
    PLoS One; 2013; 8(9):e74438. PubMed ID: 24086346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
    Turpin A; Delliaux C; Parent P; Chevalier H; Escudero-Iriarte C; Bonardi F; Vanpouille N; Flourens A; Querol J; Carnot A; Leroy X; Herranz N; Lanel T; Villers A; Olivier J; Touzet H; de Launoit Y; Tian TV; Duterque-Coquillaud M
    Br J Cancer; 2023 Dec; 129(12):1903-1914. PubMed ID: 37875732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SRRM4 gene expression correlates with neuroendocrine prostate cancer.
    Li Y; Zhang Q; Lovnicki J; Chen R; Fazli L; Wang Y; Gleave M; Huang J; Dong X
    Prostate; 2019 Jan; 79(1):96-104. PubMed ID: 30155992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.
    Lee AR; Li Y; Xie N; Gleave ME; Cox ME; Collins CC; Dong X
    Oncotarget; 2017 Apr; 8(17):27966-27975. PubMed ID: 28427194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical Models of Neuroendocrine Prostate Cancer.
    Cacciatore A; Albino D; Catapano CV; Carbone GM
    Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.
    Jing N; Du X; Liang Y; Tao Z; Bao S; Xiao H; Dong B; Gao WQ; Fang YX
    J Exp Clin Cancer Res; 2024 May; 43(1):144. PubMed ID: 38745318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
    Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X
    Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.
    Akamatsu S; Wyatt AW; Lin D; Lysakowski S; Zhang F; Kim S; Tse C; Wang K; Mo F; Haegert A; Brahmbhatt S; Bell R; Adomat H; Kawai Y; Xue H; Dong X; Fazli L; Tsai H; Lotan TL; Kossai M; Mosquera JM; Rubin MA; Beltran H; Zoubeidi A; Wang Y; Gleave ME; Collins CC
    Cell Rep; 2015 Aug; 12(6):922-36. PubMed ID: 26235627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
    DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
    Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular events in neuroendocrine prostate cancer development.
    Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
    Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
    Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
    Front Immunol; 2021; 12():622001. PubMed ID: 33737929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
    Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen.
    Fraser JA; Sutton JE; Tazayoni S; Bruce I; Poole AV
    Sci Rep; 2019 Dec; 9(1):19076. PubMed ID: 31836808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycomb-mediated silencing in neuroendocrine prostate cancer.
    Clermont PL; Lin D; Crea F; Wu R; Xue H; Wang Y; Thu KL; Lam WL; Collins CC; Wang Y; Helgason CD
    Clin Epigenetics; 2015; 7(1):40. PubMed ID: 25859291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.